First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy

NCT02644278 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: VX-984 120 mg + PLD 40 mg/m^2
DRUG: VX-984 240 mg + PLD 40 mg/m^2
DRUG: VX-984 480 mg + PLD 40 mg/m^2
DRUG: VX-984 720 mg + PLD 40 mg/m^2

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]